Zalicus (ZLCS +9.5%) trades up today after saying it's initiated the second of two Phase 2a...

|By:, SA News Editor

Zalicus (ZLCS +9.5%) trades up today after saying it's initiated the second of two Phase 2a clinical studies with Z160, a selective N-type calcium channel blocker designed to potentially treat chronic neuropathic pain.